JÄN-11-2005 10:59

ALCATEL USA INC.

RECEIVED
CENTRAL FAX CENTER

972 477 9328 P.

P.05/06

JAN 1 1 2005

PTOSB/26 (09-04)
Approved for use through 07/21/2006, CMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Papersonic Reduction Act of 1995, no persons and respond to a collection of information unless it displays a valid CMB occurred number.

TERMINAL DISCLAUMED TO OBVIDE A ROLLE BATTERIA.

TERMINAL DISCLAIMER TO OBVIATE A DOUBLE PATENTING REJECTION OVER A "PRIOR" PATENT	Doctor Number (Optional) 134922 CNT2
in re Application of: Geoffrey C. Stone	
Application No.: 10/791,178	
Filed: 03/01/2004	
For: Self-Canfiguring Communication Network	
The owner", Alcate!	
In making the above doctaimer, the owner does not disclaim the terminal part of the term of any patent granted on the instant application that would extend to the expiration date of the full statutory term as defined in \$5 U.S.C. 154 and 173 of the prior patent, "as the term of said prior patent is presently shortened by any terminal disclaimer," in the event that said prior patent later: expired for failure to pay a maintenance fee: is held unenforceable: is found invalid by a count of competent jurisdiction; is statutority disclaimed in whole or terminally disclaimed under 37 CFR 1.321; has all claims canceled by a reexamination cordicate; is relissued; or is in any manner terminated prior to the expiration of its full statutory term as presently shortened by any terminal disclaimer.	
Check either box 1 or 2 below, if appropriate.	
1. Tor submissions on behalf of a bissiness/organization (e.g., corporation, partnership, university, government agency, sto.), the undersigned is empowered to act on behalf of the business/organization.	
I hereby decisine that all statements made herein of my own knowledge are true and that all statements made on information end belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeepardize the validity of the application or any patent issued thereon.	
2. The undersigned is an attorney or agent of record. Reg. No.	
Signature	1-11-05 Date
Craig A. Hoersten Typed or printed name	
	972.519.5143
	Tolophone Number
✓ Terminal disclaimer fee under 37 CFR 1.20(d) included.	
WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.	
*Statement under 37 CFR 3.73(b) is required if terminal disclaimer is signed by the assignee (owner). Form PTO/3B/90 may be used for making this certification. See MPEP § 324.	

This collection of information is required by 37 CFR 1.321. The information is required to obtain or retain a benefit by the public which is to fife (and by the USPTO to process) an application. Confidentially is governed by 35 U.S.C. 123 and 37 CFR 1.11 and 1.14. This obsertion is established to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the briddhald case. Any comments in the amount of time will vary depending upon the briddhald case. Any comments in the amount of time will vary depending upon the briddhald case. Any comments for reducing this burden, should be sent to the Chief information Officer, U.S. Patient and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS, SEND TO: Commissioner for Patients, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need easistance in complating the form, call 1-800-PTO-9199 and select option 2.